Your browser doesn't support javascript.
loading
Myeloperoxidase Inhibition Reverses Biomarker Profiles Associated With Clinical Outcomes in HFpEF.
Michaëlsson, Erik; Lund, Lars H; Hage, Camilla; Shah, Sanjiv J; Voors, Adriaan A; Saraste, Antti; Redfors, Björn; Grove, Erik L; Barasa, Anders; Richards, A Mark; Svedlund, Sara; Lagerström-Fermér, Maria; Gabrielsen, Anders; Garkaviy, Pavlo; Gan, Li-Ming; Lam, Carolyn S P.
Affiliation
  • Michaëlsson E; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Lund LH; Department of Medicine, Cardiology Unit, Karolinska Institutet, Stockholm, Sweden.
  • Hage C; Department of Medicine, Cardiology Unit, Karolinska Institutet, Stockholm, Sweden; Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
  • Shah SJ; Division of Cardiology, Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Voors AA; University of Groningen, Groningen, the Netherlands.
  • Saraste A; Heart Center, Turku University Hospital, University of Turku, Turku, Finland.
  • Redfors B; Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
  • Grove EL; Department of Cardiology, Aarhus University Hospital, Aarhus, Denmark; Faculty of Health, Aarhus University, Aarhus, Denmark.
  • Barasa A; Department of Medicine, Glostrup Hospital, Copenhagen, Denmark.
  • Richards AM; Department of Medicine, University of Otago, Christchurch, New Zealand; National University Heart Centre Singapore (NUHCS), National University of Singapore, Singapore.
  • Svedlund S; Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
  • Lagerström-Fermér M; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Gabrielsen A; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Garkaviy P; Early Clinical Development, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden.
  • Gan LM; Department of Cardiology, Sahlgrenska University Hospital, Gothenburg, Sweden; Department of Molecular and Clinical Medicine, Institute of Medicine, Sahlgrenska Academy at the University of Gothenburg, Gothenburg, Sweden.
  • Lam CSP; University of Groningen, Groningen, the Netherlands; National Heart Centre Singapore, Duke-National University of Singapore, Singapore. Electronic address: Carolyn.lam@duke-nus.edu.sg.
JACC Heart Fail ; 11(7): 775-787, 2023 07.
Article in En | MEDLINE | ID: mdl-37140510
Subject(s)
Key words
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Heart Failure Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Limits: Humans Language: En Journal: JACC Heart Fail Year: 2023 Document type: Article Affiliation country: Sweden
Fulltext
Add to My VHL
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Heart Failure Type of study: Clinical_trials / Prognostic_studies / Risk_factors_studies Aspects: Patient_preference Limits: Humans Language: En Journal: JACC Heart Fail Year: 2023 Document type: Article Affiliation country: Sweden